Abstract:A series of novel O-((3-arylisoxazol-5-yl) methyl) oxime derivatives were synthesized by highly regioselective dipolar cycloadditions of nitrile oxides with (E)-1-arylethan-1-one O-prop-2-yn-1-yl oxime substrates. Results showed that in the formation of (E)-N-hydroxy-3,4-dimethoxybenzimidoyl chloride, chlorinating substitution in phenyl occurred when excess N-chlorosuccinimide. The crystal structure of 10 among the series of compounds revealed it was cis-cyclization product and moiety of -C(CH3)=N-O- was E configuration. As a triclinic crystal, the twist angle between the isoxazol-5-yl ring (B) and phenyl ring (A) was 57.43°, at dihedral angles of 25.22°. Screening for anti-HBV activities of these compounds was carried out. The results showed compounds 11, 19 and 12 effectively inhibited HBeAg (IC50 =158.28± 0.02, 127.51± 0.01, and 213.26± 0.04 respectively). Compounds 11, 19 and 23 manifested stronger inhibition on HBsAg (IC50=12.68± 0.06, 61.24± 0.02, and 89.59± 0.02 μM respectively). Compound 15 was the effctivest inhibition of DNA replication (IC50=43.52±0.02 μM) among the compounds. Docking study of bioactive compounds with HBV core protein (3KXS) was carried out to explore their interaction.This study determined a new non-nucleoside analogs with inhibition of HBV.

Rational Design And Synthesis Of 2,2-Bisheterocycle Tandem Derivatives As Non-Nucleoside Hepatitis B Virus Inhibitors

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Design, Diversity-Oriented Synthesis and Biological Evaluation of Novel Heterocycle Derivatives As Non-Nucleoside HBV Capsid Protein Inhibitors.

Design, Synthesis, and Evaluation of Novel Heteroaryldihydropyrimidine Derivatives As Non‐nucleoside Hepatitis B Virus Inhibitors by Exploring the Solvent‐exposed Region

Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.

Design, Synthesis and Primary Biological Evaluation of the Novel 2-Pyridone Derivatives As Potent Non-Nucleoside HBV Inhibitors.

Synthesis and Evaluation of 3-Phenylisoxazoline Derivatives As Non-Nucleoside Hepatitis B Virus Inhibitors

Design, Synthesis and Evaluation of Pyrazole Derivatives As Non-Nucleoside Hepatitis B Virus Inhibitors

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Design and Synthesis of (3-Phenylisoxazol-5-yl)methanimine Derivatives as Hepatitis B Virus Inhibitors

Design and Synthesis of Novel Benzimidazole Derivatives As Inhibitors of Hepatitis B Virus

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

Discovery and Biological Evaluation of 2-((3-phenylisoxazol-5-yl) Methoxy) Benzamide Derivatives As Potent Nucleocapsid Inhibitors

Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors

2-Arylthio-5-iodo Pyrimidine Derivatives As Non-Nucleoside HBV Polymerase Inhibitors

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.

Design, Synthesis, and Biological Evaluation of Novel Thioureidobenzamide (TBA) Derivatives As HBV Capsid Assembly Modulators

Design and Synthesis of Bicyclo[4.3.0]nonene Nucleoside Analogues

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Synthesis and anti-hepatitis B virus activity of a novel class of thiazolylbenzimidazole derivatives.

Synthesis and Biological Evaluation of Triazolo-pyrimidine Derivatives As Novel Inhibitors of Hepatitis B Virus Surface Antigen (hbsag) Secretion